Balks H J, Conlon J M, Creutzfeldt W, Stöckmann F
Clinical Research Group for Gastrointestinal Endocrinology, Max-Planck-Gesellschaft, Federal Republic of Germany.
Eur J Clin Pharmacol. 1989;36(2):133-7. doi: 10.1007/BF00609184.
Cutaneous flushing was provoked in seven patients with metastatic carcinoid tumours and the carcinoid syndrome by an intravenous injection of pentagastrin (0.6 micrograms.kg-1 body weight). The patients were studied before and 1 h after a subcutaneous injection of the long-acting somatostatin analogue octreotide 50 micrograms (Sandostatin). The severity of the carcinoid flush in all the patients was reduced by administration of the analogue. The rise in facial temperature was 1.3 (0.3) degree C before and 0.8 (0.2) degree C after octreotide. Six patients responded to pentagastrin with a rise in the circulating neurokinin A-like immunoreactivity (NKA-LI) and five patients with a rise in circulating substance P-like immunoreactivity (SP-LI). No cutaneous flushing or rise in tachykinin concentration was observed in healthy subjects (n = 6) after injection of pentagastrin. The rise in NKA-LI in the patients was decreased by 61 (14)% and the rise in SP-LI by 54 (13)% after octreotide. Although flushing still occurred, the tachykinin response in two patients was completely abolished. The data demonstrate that the release of tachykinins from carcinoid tumours during pentagastrin-induced flushing is subject to partial inhibition by octreotide. However, the occurrence of a flush in some patients in the absence of a detectable rise in circulating tachykinins indicates that the latter peptides cannot be the sole causative agent of the carcinoid flush.
通过静脉注射五肽胃泌素（0.6微克/千克体重），激发了7例转移性类癌肿瘤和类癌综合征患者的皮肤潮红。在皮下注射长效生长抑素类似物奥曲肽50微克（善宁）之前和之后1小时对患者进行研究。给予该类似物后，所有患者类癌潮红的严重程度均降低。奥曲肽给药前面部温度升高1.3（0.3）摄氏度，给药后升高0.8（0.2）摄氏度。6例患者对五肽胃泌素反应为循环中神经激肽A样免疫反应性（NKA-LI）升高，5例患者循环中P物质样免疫反应性（SP-LI）升高。注射五肽胃泌素后，健康受试者（n = 6）未观察到皮肤潮红或速激肽浓度升高。奥曲肽给药后，患者NKA-LI的升高降低了61（14）%，SP-LI的升高降低了54（13）%。尽管仍有潮红发生，但2例患者的速激肽反应完全被消除。数据表明，在五肽胃泌素诱导的潮红过程中，类癌肿瘤释放的速激肽受到奥曲肽的部分抑制。然而，一些患者在循环速激肽未检测到升高的情况下仍出现潮红，这表明后者肽不能是类癌潮红的唯一致病因素。
